SCHEMBL2819164

SCHEMBL2819164

Cn1nc(N)c2c(-c3ccc(N)cc3)cc(C(C)(C)C)nc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.40
KIT P10721 3/20 0.40
BLK P51451 3/20 0.40
HTT P42858 2/20 0.40
LMNA P02545 1/20 0.38
KDR P35968 6/20 0.37
LCK P06239 3/20 0.37
TEK Q02763 1/20 0.37
GAA P10253 1/20 0.36
SRC P12931 6/20 0.36
ABL1 P00519 5/20 0.36
LYN P07948 2/20 0.36
FLT1 P17948 2/20 0.36
FLT4 P35916 2/20 0.36
FLT3 P36888 2/20 0.36
FYN P06241 1/20 0.36
MAPK14 Q16539 2/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2819162 0.85 MKNK1 (0.41) CSF1RKITBLKKDRLCK
SCHEMBL2821619 0.82 CSF1R (0.45) CSF1RKITBLKHTTLMNA
SCHEMBL2821445 0.77 RIPK1 (0.48) CSF1RKITBLKKDRLCK
SCHEMBL2816038 0.75 LMNA (0.46) CSF1RKITBLKLMNAMAPK14
SCHEMBL12973193 0.74 CSF1R (0.42) CSF1RKITBLKLMNAKDR
SCHEMBL2818678 0.74 ALDH1A1 (0.48) CSF1RKITBLKHTTLMNA
SCHEMBL2816625 0.74 KDR (0.73) CSF1RKITBLKKDRLCK
SCHEMBL3442468 0.73 CSF1R (0.61) CSF1RKITBLKHTTKDR
SCHEMBL2819183 0.72 MAPT (0.49) CSF1RKITBLKLMNAKDR
SCHEMBL13329767 0.71 LMNA (0.53) HTTLMNAGAANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795264-B2 Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-09-14 US claimed
US-20080064707-A1 SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-03-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064707-A1 SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME KDR, TIE1, TEK CSF1R 629/4885KIT 29/4885BLK 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.